Renasant Bank’s AstraZeneca AZN Stock Holding History

Renasant Bank’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,435	Closed	-$205K	–	179
2023 Q2	$205K	Buy	+1,435	New	+$211K	0.17%	178

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renasant Bank's AZN Position: Q3 2023 in Review

Renasant Bank sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 1,435 shares — an estimated $205K sold.

Renasant Bank first reported a position in AZN in Q2 2023 and held it in 1 quarter. The position peaked at $205K in Q2 2023. 1,074 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Renasant Bank reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
Renasant Bank sold 1,435 AstraZeneca shares in Q3 2023, an estimated $205K.
Renasant Bank first reported a position in AstraZeneca in Q2 2023 and held it in 1 quarter.
Renasant Bank's AstraZeneca position peaked at $205K in Q2 2023.
1,074 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Renasant Bank's 13F filing for Q3 2023, filed 1 Nov 2023.